Does rapidity of blood pressure lowering affect outcomes in hypertension treatment?



Hypertension affects more than 65 million Americans and is inadequately controlled in most of them. The presence of uncontrolled hypertension confers increased rates of cardiovascular mortality. The benefits of blood pressure reduction have been clearly demonstrated in many large placebo-controlled trials. Even small differences in blood pressure can reduce the number of major cardiovascular events. Data from the Study on Cognition and Prognosis in the Elderly (SCOPE), Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) study, and Systolic Hypertension in Europe (Syst-Eur) trial demonstrate that the achievement of early blood pressure reduction has long-term benefits on cardiovascular outcomes. VALUE demonstrated that blood pressure control within the first month of treatment was independently linked to cardiovascular outcomes. Similar results were obtained in the SCOPE and Syst-Eur trials when hypertensive therapy was delayed from 3 months to 2 years. The early achievement of blood pressure control should be of paramount importance both for physicians and their patients.

References and Recommended Reading

  1. 1.
    Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252.PubMedCrossRefGoogle Scholar
  2. 2.
    Fields LE, Burt VL, Cutler JA, et al.: The burden of adult hypertension in the United States, 1999 to 2000: a rising tide. Hypertension 2004, 44:398–404.PubMedCrossRefGoogle Scholar
  3. 3.
    Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003, 290:199–206.PubMedCrossRefGoogle Scholar
  4. 4.
    World Health Organization: World Health Report 2002: Reducing Risks, Promoting Healthy Life. Available at Accessed May 15, 2008.
  5. 5.
    Nesbitt SD, Julius S: Prehypertension: a possible target for antihypertensive medication. Curr Hypertens Rep 2000, 2:356–361.PubMedCrossRefGoogle Scholar
  6. 6.
    Collins R, MacMahon S: Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary heart disease. Br Med Bull 1994, 50:272–298.PubMedGoogle Scholar
  7. 7.
    Stamler J, Stamler R, Neaton JD: Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993, 153:598–615.PubMedCrossRefGoogle Scholar
  8. 8.
    Kannel WB: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996, 275:1571–1576.PubMedCrossRefGoogle Scholar
  9. 9.
    Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305–1315.PubMedCrossRefGoogle Scholar
  10. 10.
    Vasan RS, Larson MG, Leip EP, et al.: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291–1297.PubMedCrossRefGoogle Scholar
  11. 11.
    Drexler H: Factors involved in the maintenance of endothelial function. Am J Cardiol 1998, 82:3S–4S.PubMedGoogle Scholar
  12. 12.
    Unger T: The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002, 89:3A–9A; discussion 10A.PubMedCrossRefGoogle Scholar
  13. 13.
    Lande K, Os I, Kjeldsen SE, et al.: Increased platelet size and release reaction in essential hypertension. J Hypertens 1987, 5:401–406.PubMedCrossRefGoogle Scholar
  14. 14.
    Laragh JH: Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973, 55:261–274.PubMedCrossRefGoogle Scholar
  15. 15.
    Esler M, Julius S, Zweifler A, et al.: Mild high-renin essential hypertension. Neurogenic human hypertension? N Engl J Med 1977, 296:405–411.PubMedGoogle Scholar
  16. 16.
    Alderman MH, Madhavan S, Ooi WL, et al.: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991, 324:1098–1104.PubMedGoogle Scholar
  17. 17.
    Laragh JH, Baer L, Brunner HR, et al.: Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972, 52:633–652.PubMedCrossRefGoogle Scholar
  18. 18.
    Brunner HR, Laragh JH, Baer L, et al.: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972, 286:441–449.PubMedGoogle Scholar
  19. 19.
    Duprez DA: Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006, 24:983–991.PubMedCrossRefGoogle Scholar
  20. 20.
    Schelling P, Fischer H, Ganten D: Angiotensin and cell growth: a link to cardiac hypertrophy? J Hypertens 1991, 9:3–15.PubMedGoogle Scholar
  21. 21.
    Naftilan A, Pratt RE, Dzau VJ: Induction of platelet-derived growth factor A-chain and c-myc gene expression by angiotensin II in cultured smooth muscle cells. J Clin Invest 1989, 83:1419–1424.PubMedCrossRefGoogle Scholar
  22. 22.
    Dietz R, Waas W, Haberbosch W, et al.: Modulation of coronary circulation and the cardiac matrix by the renin angiotensin system. Eur Heart J 1991, 12(Suppl F):107–111.PubMedGoogle Scholar
  23. 23.
    Weber KT, Brilla CG: Factors associated with reactive and reparative fibrosis of the myocardium. Basic Res Cardiol 1992, 87(Suppl 1):291–301.PubMedGoogle Scholar
  24. 24.
    Folkow B: Physiologic aspects of primary hypertension. Physiol Rev 1982, 62:347–504.PubMedGoogle Scholar
  25. 25.
    Brush JE Jr, Cannon RO, Schenke WH, et al.: Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1988, 319:1302–1307.PubMedGoogle Scholar
  26. 26.
    Levy D, Garrison RJ, Savage DD, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561–1566.PubMedGoogle Scholar
  27. 27.
    Julius S, Nesbitt SD, Egan BM, et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006, 354:1685–1697.PubMedCrossRefGoogle Scholar
  28. 28.
    Schunkert H: Pharmacotherapy for prehypertension—mission accomplished? N Engl J Med 2006, 354:1742–1744.PubMedCrossRefGoogle Scholar
  29. 29.
    Sever PS, Poulter NR, Elliott WJ, et al.: Blood pressure reduction is not the only determinant of outcome. Circulation 2006, 113:2754–2774.PubMedCrossRefGoogle Scholar
  30. 30.
    Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.PubMedCrossRefGoogle Scholar
  31. 31.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002, 288:2981–2997.CrossRefGoogle Scholar
  32. 32.
    Lithell H, Hansson L, Skoog I, et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875–886.PubMedCrossRefGoogle Scholar
  33. 33.
    Papademetriou V, Farsang C, Elmfeldt D, et al.: Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension. J Am Coll Cardiol 2004, 44:1175–1180.PubMedGoogle Scholar
  34. 34.
    Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031.PubMedCrossRefGoogle Scholar
  35. 35.
    Weber MA, Julius S, Kjeldsen SE, et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004, 363:2049–2051.PubMedCrossRefGoogle Scholar
  36. 36.
    Bloch MJ, Basile J: Analysis of recent papers in hypertension: there is value in early blood pressure reduction. J Clin Hypertens 2004, 6:598–600.CrossRefGoogle Scholar
  37. 37.
    Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757–764.PubMedCrossRefGoogle Scholar
  38. 38.
    Staessen JA, Thijs L, Fagard R, et al.: Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004, 22:847–857.PubMedCrossRefGoogle Scholar
  39. 39.
    Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.PubMedCrossRefGoogle Scholar
  40. 40.
    Oliveria SA, Lapuerta P, McCarthy BD, et al.: Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002, 162:413–420.PubMedCrossRefGoogle Scholar
  41. 41.
    Rainer D: Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin 2006, 22:1545–1553.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Administration Medical CenterWashingtonUSA

Personalised recommendations